NLS Agreement

Nanoform Finland and Nacuity Pharmaceuticals, a Texas-based clinical stage pharmaceutical company, have signed a Technology Proof of Concept agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates. This work will explore the feasibility of the patented CESS process […]

LIDDS has announced that an agreement has been signed with Johnson & Johnson Enterprise Innovation to develop an oncology product based on the NanoZolid technology for an undisclosed indication. “I am pleased that we have signed this exciting collaboration,” says Monica Wallter, CEO of LIDDS in the company’s press release. “LIDDS favorable and clinically validated […]

Beactica Therapeutics and Oscotec, a Korean drug development company, have announced a new research development and licensing agreement. The two companies will initially jointly collaborate concerning research and early preclinical development of novel anticancer drug candidates arising out of Beactica’s LSD1 programme. Oscotec may thereafter opt to take full responsibility for clinical development and commercialization, […]

The agreement gives BTC Health, through its investment company BioImpact Pty Ltd, exclusive rights to distribute NEOLA within Australia, New Zealand, Singapore and select countries in the Pacific, as soon as the regulatory process is in place. BTC Health (BTC) is an Australian company listed on the Australian Stock Exchange (ticker: BTC). The company has […]

Arla Foods Ingredients Group P/S and Zerion have entered into an agreement covering the supply of Arla’s novel ingredient Lacprodan BLG. Zerion utilizes this highly purified protein as a critical component in its patented Dispersome technology that enables poorly soluble drugs to reach their true therapeutic potential, it states. The agreement marks an important milestone […]

Ubiquigent has entered into a license agreement with Medivir for Medivir’s preclinical USP7 research program. Under the terms of the agreement, Medivir has granted Ubiquigent an exclusive worldwide license to develop and commercialize the program including all associated compounds across any therapeutic indication(s) in return for agreed revenue share upon successful development or commercialization by […]